Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
A topical androgen receptor ANTAGONIST: it blocks androgen signalling at the hair follicle rather than providing any. It has no anabolic action whatsoever and, if anything, opposes androgen activity locally. Used purely to offset the cosmetic cost of a cycle, so it does not move the natural ceiling. Rated 1 (basically natty).
Overview
A non-steroidal topical androgen receptor antagonist originally developed by Roussel Uclaf for androgen-dependent skin conditions. It is the community answer to the one problem finasteride cannot solve, because it blocks the receptor itself rather than the enzyme that makes DHT, it theoretically works against ANY androgen, including DHT-derivatives and trenbolone, where 5-AR inhibitors are useless. That theory rests almost entirely on animal data. There is no published human trial.
Important Warnings
- •NO published human clinical trial exists for efficacy or safety
- •NOT approved for human use in any jurisdiction: research chemical only
- •The 50mg/day figure is community-derived, not a validated clinical dose
- •Product concentration and purity are unverified; you may not be applying what the label claims
- •Long-term safety is entirely unknown. There is no surveillance data
- •If systemic absorption exceeds design assumptions, systemic androgen blockade (low libido, gynecomastia) is the plausible failure mode
- •Efficacy evidence is animal-model data from the 1990s, not human results
Purpose & Use Cases
The Only Theoretical Option Against Non-5AR Androgens
Finasteride cannot help on DHT-derivatives (nothing left to block), can worsen loss on 19-nors, and does nothing against trenbolone. A receptor antagonist is the only mechanism that theoretically applies across all of them. This is the entire reason the compound has a following.
Avoiding Systemic Anti-Androgen Effects
The stated design goal was a topical antiandrogen that acts locally and is inactivated systemically, avoiding the sexual and hormonal side effects of systemic antiandrogens. The original animal work supports local-without-systemic activity in that model; human confirmation does not exist.
Benefits
- Blocks the androgen receptor directly. Theoretically effective regardless of which androgen is driving the loss
- The only mechanism that theoretically applies to DHT-derivatives, 19-nors and trenbolone
- In the original animal work, topical application produced dose-dependent local antiandrogen activity without systemic antiandrogenic effects or altered testosterone at higher doses
- Does not affect the HPT axis or require PCT
- Avoids the 5-AR/neurosteroid mechanism associated with finasteride side-effect reports
Good to Know
Why people reach for it: the finasteride gap
Finasteride blocks the enzyme that converts testosterone to DHT. That does nothing when the androgen attacking your follicles is already a DHT-derivative (Masteron, Winstrol, Anavar, Proviron), is a 19-nor where blocking 5-AR makes things worse, or is trenbolone which is not 5-alpha-reduced at all. A receptor blocker is the only mechanism that theoretically covers those cases.
The evidence base is animal data from the 1990s
The foundational study (Battmann et al. 1994) showed high affinity for hamster prostate and flank-organ androgen receptors, with topical application producing potent dose-dependent regression of flank organ area at doses as low as 1 microgram per animal and no systemic antiandrogenic activity up to 100 micrograms per animal. That is a hamster flank organ, not a human scalp, and there is no published human efficacy trial.
Local-not-systemic is a design goal, not a verified human property
The whole safety case rests on the compound being inactivated before it acts systemically. That held in the original animal model. Nobody has measured it in humans at the doses and volumes people actually apply, so the systemic risk is genuinely unquantified rather than known to be low.
You do not know what you are applying
There is no pharmaceutical-grade RU58841. Every source is a research-chemical vendor, and independent testing of this market has repeatedly found products that deviate from label claims. The stated 50mg/day is meaningless if the solution is not the concentration it claims to be.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 25 – 25 mg/day |
| Intermediate | 50 – 50 mg/day |
CRITICAL CAVEAT: these figures are COMMUNITY-DERIVED, not clinical. There is no established human dose for RU58841 because no published human dose-ranging trial exists. 50mg/day applied once daily is simply the figure most frequently repeated across research-chemical vendors and community documentation, and the common vendor presentation is a 50mg/mL topical solution. The original preclinical work (Battmann 1994) used microgram quantities per animal in a hamster flank-organ model. Those figures do not scale to a human scalp in any validated way. Anyone using this is self-experimenting with an unapproved compound at a dose nobody has validated, from a supplier whose actual concentration and purity are unverified.
No published human pharmacokinetic data exists. The design intent described in the original work was rapid metabolic inactivation once the compound reaches systemic circulation, so that the antiandrogen effect stays local to the scalp, but this has never been characterised in humans, and the degree of systemic exposure at the doses people actually apply is unknown.
Side Effects
Unknown long-term safety profile
commonThis is the honest headline risk. There is no published human safety data, no long-term toxicology in humans, and no post-market surveillance. Absence of reported harm is not evidence of safety when nobody is systematically looking.
None available. This is an irreducible risk of using an unapproved research compound.
Systemic anti-androgen effects if absorption exceeds design assumptions
uncommonThe premise is that the compound is inactivated before it can act systemically. If that fails at real-world application volumes, the effect would be systemic androgen receptor blockade. The opposite of what someone on cycle wants, with potential for reduced libido and gynecomastia. Human absorption at these doses has not been characterised.
Use the lowest effective volume. Discontinue if libido or gynecomastia symptoms appear.
Scalp irritation / contact dermatitis
commonIrritation, redness and dryness, frequently attributed to the alcohol/propylene-glycol vehicles these solutions are dissolved in rather than the compound itself.
Reduce application volume or change vehicle.
Product quality and dosing uncertainty
commonEvery supplier is a research-chemical vendor operating under varying quality control. The concentration and purity of what arrives may not match the label, meaning the actual dose is unknown even if the protocol is followed exactly.
Third-party testing where available. There is no way to fully mitigate this.
General Mitigation Strategies
The dominant risk here is not a specific side effect. It is the complete absence of human data. There is no published human trial, no established dose, no characterised pharmacokinetics, no long-term safety profile, and no regulated supply chain. Everything known about efficacy comes from animal models from the 1990s and from self-reported community experience. Anyone using this should understand they are the experiment.
Post Cycle Therapy (PCT)
No HPT axis interaction documented. No PCT implications.
How It Works
RU58841 competes with DHT and testosterone for binding at the androgen receptor in the hair follicle. By occupying the receptor without activating downstream transcription, it prevents androgen-mediated follicular miniaturization. This is mechanistically different from finasteride and dutasteride, which reduce the amount of DHT produced but leave the receptor available to whatever androgen remains. The reason a receptor blocker is theoretically compound-agnostic while a 5-AR inhibitor is not.
Hormonal & Androgenic Profile
N/A: an androgen receptor ANTAGONIST, the pharmacological opposite of an anabolic.
Not an aromatase or estrogen tool. Note that if meaningful systemic androgen receptor blockade did occur, the resulting androgen/estrogen imbalance is the plausible route to gynecomastia, the same way other antiandrogens produce it.
None, and that is the entire point. RU58841 works DOWNSTREAM of 5-alpha-reductase by blocking the receptor the androgen would bind. That is why it theoretically applies where finasteride cannot: DHT-derivatives (already DHT, nothing to block), 19-nors (where finasteride can worsen loss), and trenbolone (not 5-alpha-reduced at all).
No documented cardiovascular effect. Also no human data establishing its absence.
Fundamentals
Reference on the practices relevant to RU58841: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- RU58841 + Minoxidil: different mechanisms, the common community pairing
- RU58841 where finasteride cannot work: DHT-derivatives, 19-nors, trenbolone
- Consider proven options (minoxidil, finasteride, dutasteride) before an unapproved research chemical
Legal Status
Never approved for human use in any jurisdiction. Sold only by research-chemical suppliers, labelled "not for human consumption". There is no pharmaceutical-grade product, no regulatory oversight of purity or concentration, and no published human efficacy trial.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Not named individually on the List, but WADA S0 covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", explicitly including drugs under or discontinued from clinical development, and it is prohibited at all times. RU58841 has no approval anywhere and its development was never completed, so tested athletes should treat it as caught by S0 despite having no performance-enhancing action of its own.